Clinical Trial Calendar

Clinical trials are binary speculative events that could make or break biotech stocks. Therefore, knowing the timing of announcement of results for phase I, phase II and phase III clinical studies helps limit risk and maximize profits when trading/investing in biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending clinical trial catalysts. The column "Results Date" refers to the announcement timing of the clinical trial results. But not every time is the schedules and deadlines followed by the companies, because sometimes the results may be announced early if the trial is stopped early due to efficacy or there may be a delay in reporting the results if there are unexpected hurdles in completing the clinical study.
Results Date
Company Name
Early Summer 2015
Transition Therapeutics Inc.
Top-line data from phase 2 study of ELND005
Treatment for agitation and aggression in patients with Alzheimer’s disease
Q3 2015
Cara Therapeutics Inc.
Top-line efficacy data from phase 2 trial of I.V. CR845
Uremic pruritus
2H 2015
Pieris Pharmaceuticals Inc
Data from Phase I trial of PRS-080
Q3 2015
Apricus Biosciences, Inc.
Topline data from Phase 2a proof-of-concept study of RayVa
Scleroderma patients who also suffer from Raynaud's Phenomenon
2H 2015
Intra-Cellular Therapies, Inc.
Topline data from first Phase 3 trial of ITI-007
2H 2015
Galapagos NV
Topline results from phase 1 study of GLPG1837
Cystic fibrosis patients who carry class III/IV mutations
2H 2015
Chimerix, Inc.
Report results from phase III study of Brincidofovir, dubbed SUPPRESS
Prevention of cytomegalovirus (CMV) infection in hematopoietic cell transplant recipients
Q3 2015
Vital Therapies, Inc
Topline data from Phase 3 study of VTI-208
Alcohol induced liver decompensation
Q3 2015
Anacor Pharmaceuticals, Inc.
Top-line data from Phase 3 studies of AN2728
Mild-to-moderate atopic dermatitis
Q3 2015
Conatus Pharmaceuticals Inc
Top line results from Phase 2 trial of Emricasan
Portal Hypertension
Late 2015
Affimed N.V.
Initial data from phase 2a trial of AFM13
Hodgkin lymphoma
Late 2015
Biomarin Pharmaceutical Inc.
Full results from phase 1/2 study with cerliponase alfa
CLN2 disorder, a late infantile form of Batten Disease
Late 2015
Revance Therapeutics, Inc.
Top-line data from Phase 2 study of RT002
Glabellar Lines, more commonly known as frown lines
Late 2015
Adamas Pharmaceuticals Inc
Topline data from phase III studies for ADS-5102
Parkinson's disease who have LID
Late 2015
Apricus Biosciences, Inc.
Top-line data from phase 2b clinical trial with Fispemifene
Secondary hypogonadism in males
Late 2015
Cara Therapeutics Inc.
Top-line data from phase 2 trial of Oral CR845
Sep 2015
Zosano Pharma Corporation
Top-line data from phase 2 trial of ZP-Glucagon
Severe hypoglycemia in diabetics
Late 2015
Immune Pharmaceuticals Inc.
Initial data from phase 2 trial of Bertilimumab
Bullous Pemphigoid